Caricamento quotazioni...
Previsioni
| Acquista |
21 |
| Mantieni |
3 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Argenx posts high Vyvgart revenues, operating result below analysts' expectations
In the third quarter Argenx's revenue rose by over 50% year-on-year to $1.72 billion thanks to Vyvgart; operating income climbed to $486 million but missed the Bloomberg consensus. Net income attributable to shareholders was $506 million due to a tax effect. Higher R&D and commercialization costs and a recent trial termination in Sjögren’s weigh on the stock, which turned positive after initial losses. Argenx plans a label expansion for Vyvgart Hytrulo and a regulatory study in dermatomyositis; Efgartigimod Alfa remains the main source of revenue. » Altro su finanzen.net
arGEN-X: revenue boom driven by Vyvgart, earnings hit by higher R&D and sales expenses
In the third quarter arGEN-X’s revenue rose by more than 50% to $1.72 billion, almost entirely driven by sales of the drug Vyvgart. Operating income grew 40% year-on-year to $486 million but fell short of analysts’ expectations. The main reasons for margin pressure are increased research and marketing costs. Net income attributable to shareholders was $506 million, up from $344 million a year earlier. CEO Karen Massey emphasizes that Vyvgart is the business foundation and that further growth opportunities exist. » Altro su finanzen.net
Argenx shares recover slightly after phase-III trial flop
European stocks extended their recovery on Monday, supported by an agreement between Europe and China on export restrictions for hybrid cars, which could particularly benefit auto stocks. The EuroStoxx 50 rose 0.45 percent, the SMI gained 0.66 percent and the FTSE 100 climbed 0.99 percent. Argenx shares added 0.7 percent after having fallen sharply following the failure of a pivotal phase-III study. Ahold Delhaize fell nearly three percent after reports of IT problems and resulting security measures. » Altro su finanzen.net
Argenx stops phase-III study of Efgartigimod Sc in Sjögren – stock plunges
Argenx has halted the advanced phase-III study of Efgartigimod Sc for the treatment of Sjögren’s syndrome, after which the share price fell by double digits. At the same time the biotech reported positive trial results for a potential celiac disease drug, but could not prevent the sell-off. » Altro su finanzen.net
Argenx halts UNITY study of Vyvgart — shares tumble 17%
Argenx has stopped the late‑stage UNITY study seeking approval of Vyvgart for Sjögren’s syndrome on the recommendation of an independent data monitoring committee due to futility. The move removes a potential revenue source and is likely to materially reduce peak sales forecasts for Vyvgart; the stock fell about 17% on the news. At the same time, Argenx reported a positive result: the primary endpoint of a phase‑2 study of FB102 in celiac disease was met, but this is secondary in significance given the study halt. » Altro su deraktionaer.de
Dati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 1,52 Mld | - |
| Utile lordo | 1,37 Mld | - |
| Utile netto | 446,72 Mln | - |
| EBITDA | 475,86 Mln | - |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 55,3 Mld € |
Numero di azioni | 62,89 Mln |
Massimo/minimo a 52 settimane | 929,43 € - 645,79 € |
| Dividendi | No |
Beta | -0,02 |
Rapporto P/E | 44,50 |
Rapporto PEG | 2,32 |
Rapporto P/B | 7,06 |
Rapporto P/S | 13,29 |
Profilo aziendale
argenx SE, una società di biotecnologie, si concentra sullo sviluppo di varie terapie per il trattamento delle malattie autoimmuni negli Stati Uniti, nei Paesi Bassi, in Belgio, Giappone, Svizzera, Germania e Francia. Il suo principale candidato prodotto è efgartigimod per il trattamento di pazienti con miastenia gravis, trombocitopenia immune, pemfigo volgare e polineuropatia demielinizzante infiammatoria cronica in studi clinici di Fase III; pemfigoide bolloso e miopatia infiammatoria idiopatica in studi clinici di Fase II/III; e ENHANZE SC in studio preclinico. La società sta inoltre sviluppando programmi di innovazione in immunologia, tra cui cusatuzumab per il cancro ematologico, nonché per le MDS ad alto rischio; ARGX-119, un anticorpo che si rivolge alla fase della chinasi tirosinica specifica del muscolo; ARGX-117 per indicazioni autoimmuni gravi; ARGX-118 per l'infiammazione delle vie aeree; e ARGX-120 per il trattamento delle malattie autoimmuni. Inoltre, i suoi candidati prodotto in partnership includono ARGX-115 per il trattamento del cancro; ARGX-112 per il trattamento del recettore dell'interleuchina-22; e ARGX-114, un anticorpo diretto contro il recettore MET. La società ha una partnership strategica con AbbVie S.À.R.L., Zai Lab Limited e LEO Pharma A/S, e un accordo di collaborazione e licenza con Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V. e Shire International GmbH. argenx SE è stata costituita nel 2008 e ha sede a Breda, nei Paesi Bassi.
| Nome | Argenx SE |
| CEO | Karen Massey |
| Sede centrale | Amsterdam,
nh Paesi Bassi |
| Sito web | |
| Settore | Sanità |
| Industria | Biotecnologia |
| Quotazione in borsa | 10/07/2014 |
| Dipendenti | 1863 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Euronext | ARGX.BR |
Pnk | ARGNF |
Brussels Stock Exchange | ARGX.BR |
Frankfurt | 1AE.F |
Düsseldorf | 1AE.DU |
London | 0QW0.L |
München | 1AE.MU |
Wien | ARGX.VI |